Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
Publication/Presentation Date
12-9-2003
Abstract
BACKGROUND: Both stenting and the glycoprotein IIb/IIIa inhibitor abciximab improve outcomes for patients undergoing primary angioplasty for acute myocardial infarction (AMI). However, the cost-effectiveness of these strategies is unknown.
METHODS AND RESULTS: We performed a prospective cost-utility analysis among US participants in the CADILLAC trial. Patients with AMI (n=1703) were randomized to stenting versus balloon angioplasty (PTCA) and abciximab versus no abciximab according to a 2-by-2 factorial design. Total 1-year costs and lifetime incremental cost-effectiveness ratios, measured as cost per quality-adjusted year of life (QALY) gained, were calculated. Compared with PTCA, stenting increased procedural costs by 1148 dollars and initial hospital costs by 1384 dollars (both P
CONCLUSIONS: Primary stenting is a highly cost-effective treatment for AMI. The cost-effectiveness of abciximab in this setting is uncertain and depends primarily on whether long-term survival is enhanced.
Volume
108
Issue
23
First Page
2857
Last Page
2863
ISSN
1524-4539
Published In/Presented At
Bakhai, A., Stone, G. W., Grines, C. L., Murphy, S. A., Githiora, L., Berezin, R. H., Cox, D. A., Stuckey, T., Griffin, J. J., Tcheng, J. E., Cohen, D. J., & CADILLAC Investigators (2003). Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial. Circulation, 108(23), 2857–2863. https://doi.org/10.1161/01.CIR.0000103121.26241.FA
Disciplines
Medicine and Health Sciences
PubMedID
14610016
Department(s)
Department of Medicine
Document Type
Article